<SEC-DOCUMENT>0001493152-26-006521.txt : 20260213
<SEC-HEADER>0001493152-26-006521.hdr.sgml : 20260213
<ACCEPTANCE-DATETIME>20260213060606
ACCESSION NUMBER:		0001493152-26-006521
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20260213
FILED AS OF DATE:		20260213
DATE AS OF CHANGE:		20260213

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OKYO Pharma Ltd
		CENTRAL INDEX KEY:			0001849296
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41386
		FILM NUMBER:		26628699

	BUSINESS ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
		BUSINESS PHONE:		44 (0) 207 495 2379

	MAIL ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO RULE 13a-16 OR 15d-16</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>February
2026</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
File Number:</B> 001-41386</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>OKYO
Pharma LTD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in Its Charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>9<SUP>th
</SUP>Floor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>107
Cheapside</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>London
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>EC2V
6DN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of registrant&rsquo;s principal executive office)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746; Form 40-F &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
CONTAINED IN THIS REPORT ON FORM 6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 13, 2026, OKYO Pharma LTD (the &ldquo;<U>Company</U>&rdquo;) issued this 6K announcing the pricing of an underwritten public
offering (the &ldquo;Offering&rdquo;) of 10,815,000 ordinary shares at an offering price of $1.85 per ordinary share. The Company has
granted the underwriter a 30-day option to purchase up to an additional 1,622,250 ordinary shares at the public offering price, less
underwriting discounts and commissions. The gross proceeds to the Company from the Offering, before deducting offering expenses payable
by the Company and discounts, will be approximately $20 million. Assuming full exercise by the underwriter of its option to purchase
additional ordinary shares, the gross proceeds to the Company from the Offering would be approximately $23 million, before deducting
offering expenses payable by the Company and discounts. The Company intends to use the net proceeds from the Offering primarily for clinical
development of its product candidates, general corporate purposes and working capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being
furnished and shall not be deemed &ldquo;filed&rdquo; for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise
subject to the liabilities of that Section, This report on Form 6-K is hereby incorporated by reference into the Company&rsquo;s Registration
Statement on Form F-3 (Reg. No. 333-293145)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
    Pharma LTD</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    February 13, 2026</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Keeren Shah</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keeren
    Shah</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><A HREF="ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">News Announcement, dated February 12, 2026</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><IMG SRC="ex99-1_001.jpg" ALT=""></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>OKYO
Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">London
and New York, NY, February 12, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational
therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced the pricing of an underwritten
public offering (the &ldquo;Offering&rdquo;) of 10,815,000 ordinary shares at an offering price of $1.85 per ordinary share. The Company
has granted the underwriter a 30-day option to purchase up to an additional 1,622,250 ordinary shares at the public offering price, less
underwriting discounts and commissions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
gross proceeds to the Company from the Offering, before deducting offering expenses payable by the Company and discounts, will be approximately
$20 million. Assuming full exercise by the underwriter of its option to purchase additional ordinary shares, the gross proceeds to the
Company from the Offering would be approximately $23 million, before deducting offering expenses payable by the Company and discounts.
The Company intends to use the net proceeds from the Offering primarily for clinical development of its product candidates, general corporate
purposes and working capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Piper
Sandler &amp; Co. is serving as the sole manager for the Offering. The Offering is expected to close on or about February 17, 2026, subject
to the satisfaction of customary closing conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities are being offered and sold pursuant to a shelf registration statement on Form F-3 (File No. 333-293145), including a base
prospectus, filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on February 2, 2026, and declared effective
on February 10, 2026. The Offering is being made only by means of a preliminary prospectus supplement and the accompanying base prospectus,
as may be further supplemented by any free writing prospectus that the Company may file with the SEC. The final prospectus supplement
relating to the Offering will be filed with the SEC and will also be available on the SEC&rsquo;s website. Copies of the preliminary
prospectus supplement, the final prospectus supplement (when available) and the accompanying base prospectus relating to the Offering
can also be obtained from Piper Sandler &amp; Co. at 350 North 5<SUP>th</SUP> Street, Suite 1000, Minneapolis, MN 55401, Attn: Prospectus
Department, or via email at <U>prospectus@psc.com</U> or telephone at (800) 747-3924.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities
in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under
the securities laws of such state or jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
OKYO Pharma</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OKYO
Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic
corneal pain (NCP) and inflammatory eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO is focused
on the discovery and development of novel molecules to treat neuropathic corneal pain and other ocular diseases. OKYO recently completed
a successful phase 2 trial of its flagship drug urcosimod in patients with NCP and plans to initiate a ~150 subject Phase 2b/3 multiple-dose
study of urcosimod to treat NCP in the first half of this year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements
in this press release may be &ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties
that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking
statements are not historical facts but rather are based on the Company&rsquo;s current expectations, estimates, and projections about
its industry; its beliefs; and assumptions. Words such as &lsquo;anticipates,&rsquo; &lsquo;expects,&rsquo; &lsquo;intends,&rsquo; &lsquo;plans,&rsquo;
&lsquo;believes,&rsquo; &lsquo;seeks,&rsquo; &lsquo;estimates,&rsquo; and similar expressions are intended to identify forward-looking
statements. These forward-looking statements reflect the current beliefs and expectations of management and include statements regarding
the closing of the Offering and the expected use of proceeds from the Offering. These statements are not guarantees of future performance
and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company&rsquo;s control, are
difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements.
The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements,
which reflect the view of the Company only as of the date of this press release. Forward-looking statements are subject to risks and
uncertainties that may cause the Company&rsquo;s actual activities or results to differ materially from those indicated or implied by
any forward-looking statement, including, without limitation, due to risks and uncertainties related to market conditions and the satisfaction
of closing conditions related to the Offering, risks disclosed in the section titled &ldquo;Risk Factors&rdquo; included in the preliminary
prospectus supplement filed with the SEC on February 12, 2026, and risks disclosed in other documents the Company files from time to
time with the SEC. The forward-looking statements made in this announcement relate only to events as of the date on which the statements
are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements
to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or
by any appropriate regulatory authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
further inquiries:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
Pharma Ltd</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
Spencer, Business Development, and Investor Relations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+44
(0) 207 495 2379</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
<U>info@okyopharma.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  R -D# 2(  A$! Q$!_\0
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M#.)&N9%;YC<D'*C/\'WFZG //ZGV5E;Z=:0VMI!':VL*".*&% B(H& J@<
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M\:E@"A;=D'E6<=0*Z:JP]>FZ=*2O'X=TWWNVNNYC3=:E-3J)V>_Z6]-CKO\
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A%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
